INmune Bio is a biotechnology business based in the US. INmune Bio shares (INMB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.45 – a decrease of 1.38% over the previous week. INmune Bio employs 11 staff and has a trailing 12-month revenue of around $42,000.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $6.45 |
|---|---|
| 52-week range | $4.32 - $14.74 |
| 50-day moving average | $5.23 |
| 200-day moving average | $7.30 |
| Wall St. target price | $19.83 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.18 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.45 from 2025-01-17
| 1 week (2025-01-13) | -1.38% |
|---|---|
| 1 month (2024-12-20) | 46.59% |
| 3 months (2024-10-18) | 26.22% |
| 6 months (2024-07-19) | -20.17% |
| 1 year (2024-01-19) | -43.12% |
|---|---|
| 2 years (2023-01-20) | -17.52% |
| 3 years (2022-01-20) | 8.85 |
| 5 years (2020-01-17) | 13.96% |
| Revenue TTM | $42,000 |
|---|---|
| Gross profit TTM | $42,000 |
| Return on assets TTM | -44.97% |
| Return on equity TTM | -98.96% |
| Profit margin | 0% |
| Book value | $1.74 |
| Market Capitalization | $149 million |
TTM: trailing 12 months
We're not expecting INmune Bio to pay a dividend over the next 12 months.
Over the last 12 months, INmune Bio's shares have ranged in value from as little as $4.32 up to $14.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while INmune Bio's is 1.852. This would suggest that INmune Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
INmune Bio, Inc. , a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc. ; Immune Ventures, LLC; and University of Pittsburg.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Features and fees to consider before you open an account with this trading platform.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2025.
A deep dive into the highlights and limitations of Robinhood.
This account boasts commission-free trades and no minimums but has a low cash sweep rate.